Hospital
The James B. Haggin Memorial Hospital INC
The James B. Haggin Memorial Hospital INC was paid $13.83M by Medicaid between Jan 2018 and Dec 2024, across 143 billing codes. Its largest line is 74177, Computed tomography, abdomen and pelvis; with contrast material — 12% of everything it billed.
33Billing provider infoTHE JAMES B. HAGGIN MEMORIAL HOSPITAL INC
HARRODSBURG, KY 40330
HARRODSBURG, KY 40330
33aNPI1902862824assigned 04/21/2006
33bProvider typeCritical Access Hospital
28Total paid$13.83M
24GClaims269,787
24DCodes billed143
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Kentucky
Rank by total paid#7 of 16
Median peer was paid$11.73M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SNAPP, WILLIAM controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,811 | $1.39M | |
| 2019 | 28,667 | $1.71M | |
| 2020 | 30,564 | $1.59M | |
| 2021 | 50,785 | $2.17M | |
| 2022 | 52,615 | $2.41M | |
| 2023 | 44,245 | $2.53M | |
| 2024incomplete | 34,100 | $2.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12% | 1,352 | 1,236 | $1.70M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.4% | 7,393 | 6,631 | $1.29M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.9% | 4,737 | 4,024 | $1.23M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.1% | 10,037 | 9,050 | $846K |
| 80053 | Comprehensive metabolic panel | 5.7% | 27,445 | 20,832 | $793K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.8% | 12,220 | 11,049 | $528K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.4% | 10,145 | 9,661 | $472K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.8% | 1,239 | 1,157 | $386K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.7% | 4,227 | 1,092 | $378K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 928 | 819 | $377K |
| 80061 | Lipid panel | 2.4% | 8,865 | 8,426 | $339K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 18,174 | 16,060 | $302K |
131 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 3,256 | $286K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 272 | $280K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 2,436 | $232K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 4,159 | $231K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 2,842 | $202K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 3,490 | $201K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 4,216 | $167K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 1,955 | $161K |
| 84439 | 1.1% | 5,212 | $149K | |
| 87631 | 1.0% | 1,216 | $141K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,713 | $136K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,243 | $133K |
| 84484 | <1% | 2,868 | $126K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,311 | $125K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 10,270 | $123K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,139 | $121K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,831 | $114K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,545 | $111K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,700 | $110K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,589 | $107K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,959 | $100K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,631 | $93K |
| 87486 | <1% | 2,752 | $78K | |
| 82607 | <1% | 3,404 | $75K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12,807 | $71K |
| 87186 | <1% | 2,116 | $69K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,763 | $66K |
| 87077 | <1% | 2,875 | $65K | |
| 81001 | <1% | 4,796 | $63K | |
| 87581 | <1% | 2,362 | $62K | |
| 80306 | <1% | 1,017 | $55K | |
| 73630 | <1% | 865 | $52K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,023 | $48K |
| 83690 | <1% | 2,470 | $47K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 870 | $46K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,503 | $43K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 818 | $40K |
| 83605 | <1% | 896 | $38K | |
| 84703 | <1% | 1,993 | $37K | |
| 82728 | <1% | 1,655 | $37K | |
| 83540 | <1% | 1,679 | $35K | |
| 82043 | <1% | 1,950 | $31K | |
| 73610 | <1% | 457 | $29K | |
| 73560 | <1% | 428 | $29K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 973 | $29K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 758 | $29K |
| 84153 | <1% | 1,129 | $28K | |
| 85027 | <1% | 3,557 | $27K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 773 | $27K |
| 83550 | <1% | 1,434 | $26K | |
| 87070 | <1% | 1,170 | $26K | |
| 80074 | <1% | 432 | $24K | |
| 83880 | <1% | 475 | $23K | |
| 73130 | <1% | 272 | $19K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 130 | $19K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 168 | $18K |
| 85379 | <1% | 342 | $17K | |
| 85610 | <1% | 1,417 | $17K | |
| 86140 | <1% | 1,072 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 293 | $16K |
| 83735 | <1% | 871 | $15K | |
| 84481 | <1% | 471 | $14K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 13 | $12K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 107 | $12K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 713 | $11K |
| 97162 | <1% | 116 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 44 | $9K |
| 86038 | <1% | 529 | $9K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 161 | $8K |
| 85652 | <1% | 835 | $8K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $8K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $7K |
| 84145 | <1% | 140 | $7K | |
| 73030 | <1% | 115 | $6K | |
| 80050 | General health panel | <1% | 222 | $6K |
| 87430 | <1% | 330 | $6K | |
| J3490 | Unclassified drugs | <1% | 888 | $6K |
| 86703 | <1% | 123 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 509 | $6K |
| 97014 | <1% | 171 | $5K | |
| 82570 | <1% | 760 | $5K | |
| 87400 | <1% | 341 | $5K | |
| 87205 | <1% | 401 | $5K | |
| 73110 | <1% | 73 | $4K | |
| 82150 | <1% | 189 | $4K | |
| 85730 | <1% | 298 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 259 | $3K |
| 00126 | <1% | 14 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 241 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 140 | $3K |
| 87040 | <1% | 125 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 203 | $3K |
| 94760 | <1% | 361 | $3K | |
| 11043 | <1% | 22 | $2K | |
| 86431 | <1% | 160 | $2K | |
| 96376 | <1% | 66 | $2K | |
| 84480 | <1% | 128 | $2K | |
| 84403 | <1% | 57 | $2K | |
| 82550 | <1% | 102 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 63 | $1K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 507 | $1K |
| 12001 | <1% | 12 | $1K | |
| 82553 | <1% | 78 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 216 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 73 | $1K |
| 17250 | <1% | 14 | $1K | |
| 82746 | <1% | 42 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 103 | $917.13 |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 13 | $884.26 |
| 72100 | <1% | 13 | $860.88 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 81 | $854.47 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13 | $771.42 |
| 80320 | <1% | 13 | $684.11 | |
| 86677 | <1% | 14 | $643.05 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 74 | $639.37 |
| 82077 | <1% | 26 | $625.27 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 14 | $616.85 |
| 87081 | <1% | 48 | $496.74 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 59 | $484.88 |
| 85007 | <1% | 96 | $458.05 | |
| 94664 | <1% | 130 | $430.36 | |
| 82962 | <1% | 67 | $254.60 | |
| 82803 | <1% | 17 | $247.89 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 36 | $211.81 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 36 | $184.87 |
| 85651 | <1% | 17 | $183.87 | |
| 36600 | <1% | 17 | $56.70 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 12 | $46.52 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17 | $44.89 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 18 | $39.20 |
| 81015 | <1% | 14 | $3.05 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSNAPP, WILLIAM (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.